Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Patient's With Renal Impairment
An Open-Label, Randomized, Parallel Group Study to Investigate the Influence of Renal Impairment on the Efficacy and Safety of Two Doses of Bludigo™ (Indigotindisulfonate Sodium Injection, USP) 0.8% When Used as an Aid in the Determination of Ureteral Patency
-
Clinical Trial Information
Trial Contact: Britton, David
Trial Phone: 321.841.2684
-
IRB No: 20232326
Protocol Abbrev: PVP-22IC05
Principal Investigator: Lucas Wiegand, MD
Phase: Drug: Phase IV
Age Group: Adult
Treatment: Other: Saline Injection 0.9% Placebo Drug: Indigotindisulfonate sodium 0.8% Experimental contrast dye that is commonly used as a visualization aid in pelvic and abdominal surgeries and for various diagnostic procedures in medical practice. Other Names: Bludigo
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT06085183
-
Objective
This is an open label, randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency in patients with different degrees of renal impairment.
-
Key Eligibility
Inclusion Criteria:
Subjects between ≥ 18 and ≤ 85 years old
Subjects who signed a written IRB approved, informed consent form
Subjects scheduled for a surgical procedure in which the patency of the ureter must be assessed by cystoscopy following the procedure.
An estimated glomerular filtration rate (eGFR) at baseline will be determined using the Modification of Diet in Renal Disease formula (MDRD) and standardized by using individual's body surface area.
Subject's renal function will be defined based on the following criteria:
Normal subjects: eGFR of ≥90 mL/min
Mild renal impairment: eGFR 60 to 89 mL/min
Moderate renal impairment: eGFR 30 to 59 mL/min
Severe renal impairment: eGFR 15 to 29 mL/min
Subjects with normal renal function that are judged to be in good health based on medical history, physical examination, vital signs, and laboratory safety tests performed at the Screening Visit and/or prior to administration of study drug.
Patients with renal impairment (mild, moderate, or severe) who have a diagnosis of chronic (>6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in renal function) renal insufficiency meeting criteria at the Screening Visit
Exclusion Criteria:
Subjects with eGFR <15 mL/min or expected need for dialysis in the near future, or having only 1 kidney
Subjects with known severe hypersensitivity reactions to Bludigo™ or other dyes, including contrast dyes
Known history of drug or alcohol abuse within 6 months prior to the time of screening visit
Subjects, as assessed by the Investigator, with conditions/concomitant diseases precluding their safe participation in this study (e.g., major systemic diseases)
Unable to meet specific protocol requirements (e.g., scheduled visits) or subject is uncooperative or has a condition that could lead to non-compliance with the study procedures
Subject is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol
Subjects with life expectancy < 6 months
Requirement for concomitant treatment that could bias primary evaluation.
Subjects who are pregnant or breast-feeding
